Necrotizing pneumonia in children: a comprehensive narrative review of current challenges and future perspectives.

Necrotizing pneumonia (NP) represents an uncommon but severe complication of community-acquired pneumonia (CAP) in children, characterized by the destruction of lung parenchyma and formation of multiple thin-walled cavities. Despite its rarity, the incidence of pediatric NP has increased substantially over the past two decades, creating major diagnostic and treatment challenges. The COVID-19 pandemic has further altered the epidemiological landscape, with unique patterns of respiratory pathogen circulation. This narrative review synthesizes current evidence on pediatric necrotizing pneumonia through a comprehensive literature search of PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library for articles published between January 1994 and January 2025. Search terms included "necrotizing pneumonia," "necrotising pneumonia," and "cavitary pneumonia" paired with "child," "pediatric," or "paediatric," along with specific terms for etiology, diagnosis, treatment, and outcomes. We included English-language original research articles, systematic reviews, and case series with at least 10 patients. Streptococcus pneumoniae continues to dominate as the primary pathogen, accounting for 30-60% of cases, though the emergence of Mycoplasma pneumoniae as a major cause in Asia, with macrolide resistance exceeding 85%, presents new therapeutic challenges. Diagnostic approaches have evolved significantly, with lung ultrasound demonstrating comparable accuracy to CT (κ=0.85) while avoiding radiation exposure. Novel biomarkers including presepsin, copeptin, and fetuin-A show promise for early detection and prognostication. Treatment outcomes remain encouraging, with most cases (80%) successfully managed conservatively using prolonged antibiotics for a median duration of 28 days. Surgery is reserved for specific complications, and long-term outcomes are favorable with normal pulmonary function in 80-90% of children at one-year follow-up. While pediatric necrotizing pneumonia remains a serious condition, recent advances in non-invasive diagnostics, biomarker development, and understanding of post-pandemic epidemiology offer opportunities for improved outcomes. Future research should focus on validating AI-powered diagnostic tools, optimizing antimicrobial therapy in the era of resistance, and establishing evidence-based surgical intervention criteria. The integration of lung ultrasound as a radiation-free diagnostic modality represents a paradigm shift in pediatric pneumonia management.